Tag #Bristol Myers Squibb

Showing 1 to 3 of 3 results

dutchnews.nl

🌐 85% Global Worthiness

Sep 13, 01:18

Dutch Oncologists Develop Pioneering Immunotherapy Treatments, but Face Industry Opposition

Dutch oncologists have developed new immunotherapy treatments that cure more cancer patients with fewer drugs, but pharmaceutical companies are delaying wider access due to financial concerns.

Dutch Oncologists Develop Pioneering Immunotherapy Treatments, but Face Industry Opposition

Dutch oncologists have developed new immunotherapy treatments that cure more cancer patients with fewer drugs, but pharmaceutical companies are delaying wider access due to financial concerns.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

Why are these improved treatments not yet widely available, despite their success?

The primary obstacle is the reluctance of Bristol Myers Squibb (BMS), the drug license holder, to submit applications for regulatory approval. Doctors attribute this to financial concerns, as shorter treatments mean fewer drug sales. This resistance is exemplified by BMS initially supporting research but later withdrawing support, only recently stating they are "preparing" an application.

forbes.com

🌐 75% Global Worthiness

Mar 5, 13:11

BMY Stock: Strong Q4 Results Contrast with Long-Term Underperformance

Bristol Myers Squibb's stock (BMY) is up 7% year-to-date, outperforming the S&P 500, but down 9% since early 2023 due to a lower P/S ratio despite increased revenue ($48.3B) and share buybacks, driven by declining legacy drug sales and upcoming biosimilar competition for Eliquis, offset by new drugs...

BMY Stock: Strong Q4 Results Contrast with Long-Term Underperformance

Bristol Myers Squibb's stock (BMY) is up 7% year-to-date, outperforming the S&P 500, but down 9% since early 2023 due to a lower P/S ratio despite increased revenue ($48.3B) and share buybacks, driven by declining legacy drug sales and upcoming biosimilar competition for Eliquis, offset by new drugs...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do the impacts of declining sales of legacy drugs, successful new drugs, and share buybacks interact to shape BMY's current valuation?

BMY's revenue increased 5% to $48.3 billion, while share buybacks reduced outstanding shares by 6%. However, an 18% drop in the P/S ratio to 2.5x from 3.0x significantly impacted valuation. This decline is linked to decreasing sales of legacy drugs and upcoming biosimilar competition for Eliquis, offset by the success of Eliquis and newer drugs.

lemonde.fr

🌐 85% Global Worthiness

May 10, 07:10

BMS and Sanofi Pay $700 Million to Settle Plavix Lawsuit

Bristol Myers Squibb and three Sanofi subsidiaries will pay $700 million to Hawaii to settle a decade-long lawsuit alleging they withheld information about Plavix's limited effectiveness, particularly for approximately 30% of patients, including a significant portion of Hawaii's population.

BMS and Sanofi Pay $700 Million to Settle Plavix Lawsuit

Bristol Myers Squibb and three Sanofi subsidiaries will pay $700 million to Hawaii to settle a decade-long lawsuit alleging they withheld information about Plavix's limited effectiveness, particularly for approximately 30% of patients, including a significant portion of Hawaii's population.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How did the limitations of Plavix disproportionately affect specific populations, and what role did this play in the lawsuit's outcome?

Hawaii's lawsuit against BMS and Sanofi centered on claims that studies showed Plavix's ineffectiveness in about 30% of patients, disproportionately affecting those of Asian and Pacific Islander descent. The $700 million settlement, equally shared by both companies, follows a previous court ruling that found the companies deliberately hampered research into Plavix's limitations. This highlights the significant financial consequences of failing to fully disclose drug efficacy information.

Showing 1 to 3 of 3 results